Eli Lilly 2022 gains grow to 20% as it lays out plan for obesity drug, tirzepatide
Eli Lilly’s drug tirzepatide has been granted “fast track” status by the Food and Drug Administration, which means it could win approval to be prescribed as an obesity treatment as…